About RNA Diagnostics
RNA Diagnostics is a company based in Toronto (Canada) founded in 2010. RNA Diagnostics has raised $13.87 million across 5 funding rounds from investors including BDC and iGan Partners. The company has 49 employees as of May 27, 2025. RNA Diagnostics offers products and services including Veridapt DX. RNA Diagnostics operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
- Headquarter Toronto, Canada
- Employees 49 as on 27 May, 2025
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Rna Diagnostics Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$13.87 M (USD)
in 5 rounds
-
Latest Funding Round
$34.71 K (USD), Series A
Dec 19, 2024
-
Investors
BDC
& 1 more
-
Employee Count
49
as on May 27, 2025
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of RNA Diagnostics
RNA Diagnostics offers a comprehensive portfolio of products and services, including Veridapt DX.
Measures early tumor response to cancer drugs for treatment guidance.
People of RNA Diagnostics
Unlock access to complete
Unlock access to complete
Funding Insights of RNA Diagnostics
RNA Diagnostics has successfully raised a total of $13.87M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $34.71 thousand completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series A — $34,710
-
First Round
First Round
(21 Sep 2015)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2024 | Amount | Series A - RNA Diagnostics | Valuation |
investors |
|
| Nov, 2024 | Amount | Series A - RNA Diagnostics | Valuation |
investors |
|
| Sep, 2021 | Amount | Series A - RNA Diagnostics | Valuation | BDC |
Investors in RNA Diagnostics
RNA Diagnostics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include BDC and iGan Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare-focused venture capital is provided by iGan Partners.
|
Founded Year | Domain | Location | |
|
Commercial banking services for small and medium-sized enterprises are provided.
|
Founded Year | Domain | Location |
Investments & Acquisitions by RNA Diagnostics
Financial Statements - RNA Diagnostics
Rna Diagnostics Comparisons
Competitors of RNA Diagnostics
RNA Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
Frequently Asked Questions about RNA Diagnostics
RNA Diagnostics was founded in 2010 and raised its 1st funding round 5 years after it was founded.
RNA Diagnostics is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
RNA Diagnostics is a funded company, having raised a total of $13.87M across 5 funding rounds to date. The company's 1st funding round was a Series A of $8M, raised on Sep 21, 2015.
As of May 27, 2025, the latest employee count at RNA Diagnostics is 49.
RNA Diagnostics was established in 2010 in Toronto, Canada, within the biotechnology sector. Focus is placed on developing diagnostic assays to detect cancer, particularly breast cancer. The primary product, RNA Disruption Assay (RDA), is utilized to evaluate chemotherapy response by analyzing rRNA disruption levels in biopsy samples. Operations center on advancing these assays for clinical applications in oncology.
RNA Diagnostics's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
RNA Diagnostics offers Veridapt DX.
RNA Diagnostics has 2 investors. Key investors include BDC, and iGan Partners.